Skip to main content
Evotec SE logo

Evotec SE — Investor Relations & Filings

Ticker · EVT ISIN · DE0005664809 LEI · 529900F9KI6OYITO9B12 F Professional, scientific and technical activities
Open in API
Filings indexed 1,773 across all filing types
Latest filing 2022-09-20 Regulatory Filings
Country DE Germany
Listing F EVT

About Evotec SE

https://www.evotec.com/en

Evotec SE is a life science company focused on drug discovery and development in partnership with pharmaceutical and biotechnology firms. The company operates an integrated research and development value chain, utilizing proprietary technology platforms that incorporate AI-driven innovation and induced pluripotent stem cells (iPSC). Its expertise spans a wide range of therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics division, the company offers end-to-end solutions for the design, development, and manufacturing of biologic therapies, aiming to enhance their accessibility and affordability. Evotec employs flexible partnering models to accelerate the delivery of new treatments to patients with high efficiency and quality.

Recent filings

Filing Released Lang Actions
Just Evotec Biologics awarded contract from the U.S. Department of Defense under accelerated antibodies program
Regulatory Filings Classification · 1% confidence The document is a news release dated September 20, 2022, announcing that Evotec Biologics has been awarded a contract from the U.S. Department of Defense. It details the scope of the contract (pre-clinical and clinical trial services for monoclonal antibodies) and includes quotes from management. This type of announcement, which is a general corporate update about a contract award and business development, does not fit the specific definitions for financial reports (10-K, IR, ER, MRQ), shareholder actions (AGM-R, DVA, DIV), or management changes (MANG). Since it is a general corporate news item distributed via EQS, and it is not a specific regulatory filing like a Director's Dealing (DIRS) or a major shareholding change (MRQ), the most appropriate general category for a non-financial, non-governance corporate announcement that doesn't fit elsewhere is the fallback category, Regulatory Filings (RNS), as it is a formal news dissemination.
2022-09-20 English
Evotec initiates ground-breaking for new biologics facility J.POD Toulouse, France (EU)
Regulatory Filings Classification · 1% confidence The document is a news release dated September 16, 2022, announcing that Evotec SE has initiated the ground-breaking for a new J.POD® biologics manufacturing facility in Toulouse, France. It details operational plans (expected operational H2 2024), job creation, and government support. The text is formatted as a corporate news announcement, disseminated via DGAP, and contains forward-looking statements and contact information typical of such releases. It is not a formal financial report (like 10-K or IR), an earnings release (ER), or a specific regulatory filing like a Director's Dealing (DIRS) or Proxy Statement (PSI). Since it is a general corporate announcement about a business development that doesn't fit the more specific categories (like M&A, Capital Change, or Dividend), it falls best under the general Regulatory Filings/News category, which is RNS, as it is a significant, non-financial operational update disseminated via a regulatory news service (DGAP).
2022-09-16 English
Evotec expands clinical and commercial drug substance manufacturing with acquisition of Central Glass Germany
Regulatory Filings Classification · 1% confidence The document is a news release dated August 25, 2022, announcing a significant corporate action: the acquisition of Central Glass Germany by Evotec SE. This announcement details a strategic expansion, asset acquisition, and future investment plans. It is not a standard periodic financial report (like 10-K or IR), an earnings release (ER), or a formal proxy/voting document. Since it concerns a major corporate transaction (M&A activity is mentioned in the definitions, but this is an acquisition announcement, not a takeover bid), and it is disseminated via DGAP (a common channel for regulatory/corporate news), the most fitting category among the provided options is 'Regulatory Filings' (RNS) as a general corporate announcement, or potentially 'M&A Activity' (TAR) if the acquisition is considered a takeover/merger proposal. However, TAR is defined specifically as 'merger proposals or takeover bids.' This is an acquisition of a subsidiary/asset. Given the nature of the announcement—a corporate development news item disseminated broadly—and the lack of a specific category for general corporate acquisitions, RNS (Regulatory Filings/General Corporate News) is the most appropriate fallback, although it strongly resembles an M&A announcement. Since the document is substantial (7896 chars) and contains the full details of the transaction rather than just announcing a report, it is not RPA. I will classify it as RNS as it is a general corporate news release about a strategic move, which often falls under miscellaneous regulatory disclosures if not fitting a more specific category like CAP or TAR.
2022-08-25 English
Evotec SE reports results for the first half-year 2022 and provides corporate updates
Earnings Release Classification · 1% confidence The document explicitly states it reports 'results for the first half-year 2022' and contains detailed financial highlights, including Group revenues, adjusted EBITDA, and segment information for H1 2022 compared to H1 2021. This content structure is characteristic of a comprehensive financial report covering a period shorter than a full year. The document is not merely an announcement of a report (RPA) because it contains the core financial figures and analysis itself, rather than just linking to a separate report. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2022
2022-08-11 English
Präsentation H1 2022
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Evotec SE, H1 2022 Interim Report' and contains detailed financial statements, including income statements, balance sheets, and segment information for the first half of the fiscal year. It provides a comprehensive analysis of financial performance, operational highlights, and business outlook. As it contains substantive financial data and analysis for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. H2 2022
2022-08-11 English
Half-yearly financial report 2022
Interim / Quarterly Report Classification · 1% confidence The document is titled 'HALF-YEAR REPORT 2022' and contains detailed financial statements, segment information, management discussion and analysis, and operational highlights for the first half of the fiscal year. It is a comprehensive report covering a period shorter than a full fiscal year, which fits the definition of an Interim/Quarterly Report (IR). H2 2022
2022-08-11 German

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.